Cargando…

Deflazacort for the treatment of Duchenne Dystrophy: A systematic review

BACKGROUND: To complete a systematic review and meta-analysis based on the clinical question: Is Deflazacort (DFZ), a prednisolone derivative, an effective therapy for improving strength, with acceptable side effects, in children with Duchenne Dystrophy (DD)? METHODS: MEDLINE, EMBASE, Current Conten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campbell, Craig, Jacob, Pierre
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC222985/ https://www.ncbi.nlm.nih.gov/pubmed/12962544 http://dx.doi.org/10.1186/1471-2377-3-7

Ejemplares similares

Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022)

The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
por: McADAM, LAURA C., et al.
Publicado: (2012)

The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy
por: Dubinin, Mikhail V., et al.
Publicado: (2020)

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
por: Griggs, Robert C., et al.
Publicado: (2016)

Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy
por: Jensen, L., et al.
Publicado: (2017)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials
por: McDonald, Craig M., et al.
Publicado: (2019)

Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life?
por: Sienko, Susan, et al.
Publicado: (2016)

Deflazacort-induced Acneiform Eruptions
por: Bashir, Mohammed Shakeel Mohammed, et al.
Publicado: (2017)

Health-Related Quality of Life in Children with DuchenneMuscular Dystrophy: A Review
por: Wei, Yi, et al.
Publicado: (2015)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

DEFLAZACORT VERSUS OTHER GLUCOCORTICOIDS: A COMPARISON
por: Nayak, Surajit, et al.
Publicado: (2008)

Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone
por: Fappi, Alan, et al.
Publicado: (2019)

Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
por: Pascual‐Morena, Carlos, et al.
Publicado: (2020)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

The Use of Virtual Reality Technologies in the Treatment of Duchenne Muscular Dystrophy: Systematic Review
por: Baeza-Barragán, Maria Rosa, et al.
Publicado: (2020)

Deflazacort in comparison to other steroids for nephrotic syndrome
por: Jat, K. R., et al.
Publicado: (2012)

Dasatinib as a treatment for Duchenne muscular dystrophy
por: Lipscomb, Leanne, et al.
Publicado: (2016)

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
por: Walter, Maggie C, et al.
Publicado: (2013)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2018)

A Systematic Review on the Role of SIRT1 in Duchenne Muscular Dystrophy
por: Domi, Elisa, et al.
Publicado: (2021)

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
por: Zhang, Tianyuan, et al.
Publicado: (2021)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

CRISPR technologies for the treatment of Duchenne muscular dystrophy
por: Choi, Eunyoung, et al.
Publicado: (2021)

Myocardial strain imaging in Duchenne muscular dystrophy
por: Earl, Conner C., et al.
Publicado: (2022)

Duchenne muscular dystrophy: Case report and review
por: Sinha, Rupam, et al.
Publicado: (2017)

Medical management of muscle weakness in Duchenne muscular dystrophy
por: Rivera, Sarah R., et al.
Publicado: (2020)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

EXERCISE TRAINING IN DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: HAMMER, Stian, et al.
Publicado: (2021)

The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review
por: Szabo, Shelagh M., et al.
Publicado: (2021)

Deflazacort Versus Prednisolone: Randomized Controlled Trial in Treatment of Children With Idiopathic Nephrotic Syndrome
por: Singhal, Ravish, et al.
Publicado: (2015)

In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort
por: Ma, Jiyuan, et al.
Publicado: (2021)

Deflazacort for Type-1 Autoimmune Hepatitis in a Korean Girl
por: Bae, Sun Hwan, et al.
Publicado: (2006)

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy
por: Kourakis, Stephanie, et al.
Publicado: (2020)

Duchenne muscular dystrophy in Italy: A systematic review of epidemiology, quality of life, treatment adherence, and economic impact
por: Orso, Massimiliano, et al.
Publicado: (2023)

Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy
por: Rotundo, Ida Luisa, et al.
Publicado: (2011)

The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review
por: Ryder, S., et al.
Publicado: (2017)

Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta‐analysis
por: Weber, Fabio J., et al.
Publicado: (2022)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c9rqkorha7ap7mmsmjhd2eol3j